Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Dragonfly Therapeutics
Conjupro Biotherapeutics, Inc.
Seagen Inc.
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
Whitehawk Therapeutics, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Pfizer
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Clasp Therapeutics, Inc.
BioNTech SE
Eli Lilly and Company
NiKang Therapeutics, Inc.
Verismo Therapeutics
USWM, LLC (dba US WorldMeds)
Poseida Therapeutics, Inc.
MacroGenics
Royal Marsden NHS Foundation Trust
SystImmune Inc.
Pheon Therapeutics
SN BioScience
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Seagen Inc.
Innate Pharma
Novartis
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
NextCure, Inc.
Seagen Inc.
University Health Network, Toronto
NeoTX Therapeutics Ltd.
Radiopharm Theranostics, Ltd
Bolt Biotherapeutics, Inc.
SystImmune Inc.
Actym Therapeutics, Inc.
Chongqing Precision Biotech Co., Ltd
NiKang Therapeutics, Inc.
City of Hope Medical Center
Pfizer
Elicio Therapeutics
GONGCHU Biotechnology Co., Ltd